CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50 mg) and expanding access to this best-in-class medicine for people living with HIV needing a PI. Categories covered include treatment failure, protease inhibitors, an overview of DRV/r, DRV/r sequencing, and side effects.
top of page
A framework to support new product introduction in national health systems
bottom of page